GENFIT, whose shares are admitted to trading on Euronext Paris and NASDAQ, has acquired the entire capital of Versantis, a Swiss-based biopharmaceutical company aimed at meeting the growing medical needs in the field of liver diseases.

The acquisition of Versantis is part of GENFIT’s strategy to become a global leader in Acute-on-Chronic Liver Failure (ACLF) and is another key step in the execution of this strategy. With the signing of this agreement, GENFIT will also expend its product portfolio to other liver diseases with significant unmet medical needs through other products developed by Versantis.

The Linklaters team was lead from Paris by partner Pierre Thomet, counsel Julien Bourmaud-Danto and associate Géraldine Gonzalvez within the Corporate/M&A practice, by Capital Markets partner Bertrand Sénéchal and associate Antoine Galvier and by Employment Law partner Géric Clomes and associate Valentine Charrier.